| Quantity: | |
|---|---|
Erlotinib hydrochloride tablet is a medication used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer. It is a targeted therapy that belongs to a class of drugs known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Erlotinib is designed to block specific proteins that play a role in the growth and spread of cancer cells.
Only confirmed
At present, the only GER1/EGFR Tyrosine kinase inhibitor proved to have survival advantages for advanced non-small cell lung cancer. It is effective for all types of non-small cell lung cancer patients.
More clinical data support
The number of clinical trials was twice that of Gefitinib. In first-line treatment of advanced NSCLC patients, Erlotinib has certain advantages over Gefitinib. There are relatively few frontline studies on icotinib hydrochloride.
Higher control rate
Compared with Gefitinib, the control rate of Chinese patients with advanced NSCLC receiving Erlotinib (first or second line) is higher, and the PFS and OS are longer.
Short half-life
Drugs metabolize quickly, do not cause drug accumulation, have good tolerance, and can improve quality of life.
Erlotinib hydrochloride tablet is a medication used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer. It is a targeted therapy that belongs to a class of drugs known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Erlotinib is designed to block specific proteins that play a role in the growth and spread of cancer cells.
Only confirmed
At present, the only GER1/EGFR Tyrosine kinase inhibitor proved to have survival advantages for advanced non-small cell lung cancer. It is effective for all types of non-small cell lung cancer patients.
More clinical data support
The number of clinical trials was twice that of Gefitinib. In first-line treatment of advanced NSCLC patients, Erlotinib has certain advantages over Gefitinib. There are relatively few frontline studies on icotinib hydrochloride.
Higher control rate
Compared with Gefitinib, the control rate of Chinese patients with advanced NSCLC receiving Erlotinib (first or second line) is higher, and the PFS and OS are longer.
Short half-life
Drugs metabolize quickly, do not cause drug accumulation, have good tolerance, and can improve quality of life.
